

Revvity unveils new era of automated tuberculosis testing

24 April 2024 | News

Substantially lowers hands-on time, allowing for increased lab productivity



American firm Revvity has announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.

The T-SPOT.TB test detects latent tuberculosis infection (LTBI) and is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot (ELISPOT) technology.

This technology has crucial steps that the World Health Organization has recently recognised as critical in ensuring reliable and accurate TB test results. These steps include washing, isolating, and counting peripheral blood mononuclear cells (PBMCs) before conducting the test.

“The ability to use the Auto-Pure 2400 platform with our T-SPOT.TB test provides labs an efficient workflow allowing latent TB testing to be run in a mid-high-volume setting, without having to compromise on the clinical performance of the test,” said Darren Sher, general manager, infectious diseases for Revvity. “With this solution, more labs can offer clinicians access to the most accurate TB diagnostic on the market.”